Bayer Schering Pharma

Bayer Schering Pharma was the pharmaceutical business and commercial identity created by Bayer after its acquisition of Schering AG in 2006. The combination joined Bayer’s existing prescription-medicine activities with Schering’s established pharmaceutical portfolio, research capabilities and international operations. It operated within Bayer HealthCare and represented Bayer’s effort to build a larger, more diversified healthcare platform alongside its consumer-health and medical-care businesses. The business inherited products and expertise across several therapeutic areas, including women’s health, diagnostic imaging, specialty medicines, cardiovascular treatments and general prescription pharmaceuticals. Schering had particularly strong historical positions in hormonal contraception, fertility-related medicines and radiology products, while Bayer contributed its own pharmaceutical research and commercial operations. The combined organization therefore had a portfolio broader than a single therapeutic specialty and was active in both primary-care and specialist markets. Bayer Schering Pharma was not an independent successor company in the same sense as Bayer AG. It was a branded operating division within Bayer’s healthcare organization. Its creation followed Bayer’s successful takeover of Schering AG in 2006 after a contested acquisition process involving Merck KGaA. Bayer subsequently integrated the acquired company and used the Bayer Schering Pharma name for its prescription-pharmaceutical operations in a number of markets. The identity was relatively short-lived. Bayer later simplified its healthcare branding and used Bayer Pharma for the prescription-pharmaceutical division. As a result, Bayer Schering Pharma is best understood as a transitional corporate brand marking the integration of Schering into Bayer rather than as a continuing standalone pharmaceutical company. Its historical importance lies in the consolidation of two major German healthcare businesses and in the transfer of Schering’s brands and research programs into Bayer’s global pharmaceutical organization.

Bayer Schering Pharma emerged from one of the most significant German pharmaceutical transactions of the 2000s. Bayer AG had an established healthcare business, while Schering AG was a long-standing Berlin-based pharmaceutical company with substantial international operations and recognized strengths in hormonal medicines, fertility treatment, diagnostic imaging and specialty pharmaceuticals. In 2006 Bayer sought to acquire Schering and initially faced competition from Merck KGaA, which had also announced an interest in the company. Bayer raised its offer and ultimately gained control of Schering. After the acquisition, Bayer incorporated Schering’s operations into Bayer HealthCare rather than preserving Schering as an independently listed pharmaceutical group. The Bayer Schering Pharma name was used to present the combined prescription-pharmaceutical activities as a unified business. This arrangement allowed Bayer to retain the commercial value and scientific capabilities associated with Schering while placing them within Bayer’s broader corporate structure. The combined business had a more extensive therapeutic and geographic footprint than Bayer’s pre-acquisition pharmaceutical operation. The portfolio reflected the complementary histories of the two companies. Schering had developed a strong position in women’s health, including oral contraceptives and fertility products, as well as in radiology and contrast media. Bayer brought its own prescription medicines, research organization and global distribution network. The resulting division also included products in cardiovascular medicine, hematology and other specialist fields. Bayer’s healthcare strategy at the time was organized around pharmaceuticals, consumer health and medical products, with Bayer Schering Pharma serving as the prescription-drug component. The brand also inherited the broader reputational and regulatory obligations of both companies. Pharmaceutical products sold under the combined organization remained subject to country-specific approvals, safety monitoring, litigation and historical product controversies connected to predecessor businesses. These issues should not automatically be treated as scandals of the Bayer Schering Pharma brand itself, particularly where the underlying events predated the 2006 creation of the identity. Bayer Schering Pharma did not remain the permanent name of Bayer’s prescription-pharmaceutical division. As Bayer simplified its healthcare architecture, it moved toward the Bayer Pharma designation. The change reflected a broader effort to make Bayer the primary global corporate brand and to reduce the complexity created by maintaining the Schering name after the integration. Bayer Schering Pharma is therefore a defunct operating brand whose assets, products and employees were absorbed into Bayer’s continuing pharmaceutical organization. Its period of use nevertheless marks the strategic integration of Schering into Bayer and the formation of a major German-based pharmaceutical platform.

1. 2010Pharmaceutical identity is streamlined to Bayer Pharma

   Bayer moved away from the Bayer Schering Pharma name as it simplified the branding of its pharmaceutical division.

   Source
2. 2006Bayer acquires Schering AG

   Bayer completed the acquisition of Schering AG following a competitive offer process. The transaction created the corporate foundation for Bayer Schering Pharma.

   Source
3. 2006Combined pharmaceutical business is branded Bayer Schering Pharma

   Bayer placed the former Schering activities within Bayer HealthCare and used Bayer Schering Pharma as the identity for the combined prescription-pharmaceutical business.

   Source

A broad, research-oriented prescription-pharmaceutical business combining Bayer’s healthcare operations with Schering’s strengths in women’s health, specialty medicines and diagnostic imaging.

• YasminHormonal contraception

  Yasmin was a combined oral contraceptive associated with Schering’s women’s-health portfolio and later marketed within Bayer’s pharmaceutical organization. Its commercial history illustrates the importance of hormonal medicines to the business inherited through the Schering acquisition. Product availability, indications and labeling varied by market.

• UltravistDiagnostic imaging

  Ultravist is an iodinated contrast medium used in diagnostic imaging. It represents the radiology and contrast-agent expertise that became part of Bayer’s pharmaceutical portfolio through the integration of Schering’s operations. The product is used in connection with imaging procedures under applicable medical supervision.

• KogenateHematology

  Kogenate was a recombinant factor VIII product for the treatment of hemophilia A. It belonged to Bayer’s specialty-pharmaceutical and hematology activities and formed part of the broader prescription portfolio associated with Bayer Schering Pharma during the integration period.

• Women’s-health and fertility medicinesWomen’s health

  The combined organization included a substantial women’s-health portfolio inherited from Schering, covering contraception and fertility-related treatments. These products were strategically important because Schering had long-standing expertise and market presence in hormonal medicine.

• 2010Retire the Bayer Schering Pharma identityStrategy

  After the acquisition and integration period, Bayer sought a simpler healthcare brand architecture centered on the Bayer name.

  What changed. The company shifted the pharmaceutical division toward the Bayer Pharma name.

  Aftermath. Bayer Schering Pharma became a historical rather than continuing operating brand, while its products and activities remained within Bayer’s pharmaceutical business.

  Source
• 2006Acquire and integrate Schering AGM&A

  Bayer sought to expand its pharmaceutical scale and strengthen its healthcare portfolio through the acquisition of Schering AG. The transaction followed competing interest from Merck KGaA.

  What changed. Bayer raised its offer, completed the takeover and integrated Schering’s pharmaceutical activities into Bayer HealthCare under the Bayer Schering Pharma identity.

  Aftermath. The combination broadened Bayer’s prescription portfolio and added Schering’s capabilities in women’s health, fertility, radiology and specialty medicines. Schering was no longer an independent listed pharmaceutical company.

  • Merck KGaA — Merck KGaA pursued Schering but did not complete the acquisition after Bayer’s higher offer prevailed.
  Source

• 2010Bayer later adopts Bayer Pharma branding

  Bayer subsequently streamlined the pharmaceutical division’s identity, replacing the Bayer Schering Pharma designation with Bayer Pharma in its corporate healthcare structure.

  Leadership change
  Source
• 2006Bayer completes acquisition of Schering

  Bayer completed its acquisition of Schering AG after raising its offer and securing the conditions required to take control. The transaction created the basis for the Bayer Schering Pharma pharmaceutical organization.

  M&AOther
  Source
• 2006Bayer introduces the Bayer Schering Pharma identity

  Following the Schering acquisition, Bayer combined the businesses under the Bayer Schering Pharma name within Bayer HealthCare.

  M&A
  Source

1. Bayer Schering Pharma
2. Schering AG
3. Bayer AG